<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02916420</url>
  </required_header>
  <id_info>
    <org_study_id>SIM-135-Ⅲ</org_study_id>
    <nct_id>NCT02916420</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma</brief_title>
  <official_title>A Multicenter, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the efficacy and safety of pomalidomide in combination with
      low-dose dexamethasone in Chinese patients with relapsed and refractory multiple myeloma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">73</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pomalidomide plus low-dose Dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>4mg/day, d1-d21, 28 days per cycle</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>≤70 years,40mg/day; &gt;70 years,20mg/day, d1、d8、d15、d22, 28 days per cycle</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a documented diagnosis of multiple myeloma

          -  Subjects must have received at least 2 prior therapies. Subjects must have undergone
             prior treatment with at least 2 cycles of lenalidomide and at least 2 cycles of
             bortezomib (either in separate regimens or within the same regimen). Subjects must
             also have documented evidence of progressive disease(PD) during or within 60 days
             (measured from the end of the last cycle) of completing treatment with the last
             anti-myeloma drug regimen used just prior to study entry.

          -  Subjects must have measurable disease: serum M-protein ≥ 5 g/L or urine M-protein ≥
             200 mg/24 hours or the involved free light chain being ≥100 mg/L when serum free light
             chain ratio (κ/λ ratio &lt; 0.26 or &gt; 1.65) is abnormal

          -  Eastern Cooperative Oncology Group (ECOG) performance status score ≤2

          -  Life expectancy &gt;3 months

          -  For female patients,

               -  naturally postmenopausal for at least 24 months, or take surgical sterilization

               -  Women of childbearing potential must:

                    1. have 2 negative pregnancy tests before initiating pomalidomide. The first
                       test should be performed within 10-14 days, and the second test within 24
                       hours prior to initiating pomalidomide

                    2. commit either to abstain continuously from heterosexual sexual intercourse
                       or to use 2 methods of reliable birth control, beginning 4 weeks prior to
                       initiating pomalidomide treatment, during therapy, and continuing for 4
                       weeks following discontinuation of pomalidomide therapy

                    3. agree to perform the pregnancy testing during the study

          -  Male patients must always use a condom during any sexual contact with females of
             reproductive potential while taking pomalidomide and for up to 4 weeks after
             discontinuing pomalidomide, even if they have undergone a successful vasectomy.
             Meanwhile male patients taking pomalidomide must not donate sperm.

          -  Subjects agree not to share medication with another person

          -  Subjects are able to adhere to the study visit schedule and other protocol
             requirements

        Exclusion Criteria:

          -  Any serious medical conditions, laboratory abnormality, or psychiatric illness that
             would prevent the patient from complying to the protocol or put the patient's safety
             at risk

          -  Evidence of uncontrolled cardiovascular disease, such as congestive heart failure,
             unstable angina, myocardial infarction within 12 months prior to enrollment

          -  Any of the following laboratory abnormalities:

               -  ANC &lt; 1×10^9/L

               -  PLT &lt; 75×10^9/L for subjects in whom &lt;50% of bone marrow nucleated cells are
                  plasma cells; or PLT &lt; 30×10^9/L for subjects in whom ≥50% of bone marrow
                  nucleated cells are plasma cells

               -  Creatinine Clearance &lt; 45 mL/min

               -  AST or ALT &gt; 3.0 x ULN

               -  Serum total bilirubin &gt; 34.2 μmol/L

               -  Corrected serum calcium &gt; 3.5 mmol/L

               -  Hemoglobin &lt; 80g/L

          -  Prior history of malignancies, other than multiple myeloma, unless the subject has
             been free of the disease for ≥ 3 years. Exceptions include the following:

               -  Basal or Squamous cell carcinoma of the skin

               -  Carcinoma in situ of the cervix or breast

               -  Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b)

          -  Serious, uncontrolled medical conditions or active infection, including but not
             limited to HIV antibody positive, HBsAg positive and HBV DNA copies &gt; 1 × 10^3,
             hepatitis C virus antibody positive, uncontrolled diabetes, patients requiring
             hemodialysis

          -  Hypersensitivity to thalidomide, lenalidomide, or dexamethasone

          -  Previous therapy with pomalidomide

          -  Peripheral neuropathy ≥ Grade 2

          -  Incidence of gastrointestinal disease that may significantly alter the absorption of
             pomalidomide

          -  Subjects who received any of the following within the last 14 days of initiation of
             study treatment: plasmapheresis, major surgery, radiation therapy, or use of any
             anti-myeloma drug therapy

          -  Use of any investigational drugs within 28 days prior to enrollment

          -  Subjects with conditions requiring chronic steroid or immunosuppressive treatment,
             such as rheumatoid arthritis, multiple sclerosis, and lupus, etc.

          -  Patients unable or unwilling to undergo antithrombotic prophylactic treatment

          -  Subjects who received an allogeneic hematopoietic stem cell transplant less than 12
             months prior to enrollment

          -  Subjects who are planning for or eligible for hematopoietic stem cell transplant

          -  Pregnant or lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lugui Qiu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood Diseases Hospital Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lugui Qiu, MD</last_name>
    <phone>86-022-27218738</phone>
    <email>qiulg@ihcams.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Blood Diseases Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2016</study_first_submitted>
  <study_first_submitted_qc>September 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2016</study_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

